(5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide

Metabolite details

Identifier

AYSGOPOJGPEGSU-UHFFFAOYSA-N

InChI Key

AYSGOPOJGPEGSU-UHFFFAOYSA-N

IUPAC name

5-(hydroxymethyl)-2-[1-hydroxy-1-(5,6,14-trihydroxy-10,13-dimethyl-1-oxo-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl)ethyl]-4-methyl-2,3-dihydropyran-6-one

Preferred name

(5alpha,6beta,14alpha,20R,22R)-5,6,14,20,27-Pentahydroxy-1-oxowith-24-enolide

INN name

—

Synonym

—

ChEBI

CHEBI:175884

Reactome pathways

• No Reactome pathways listed for this metabolite.

Observed in studies

• Bioaccumulation of therapeutic drugs by human gut bacteria: cross-feeding metabolite analysis (FIA-MS) (E.rectale;S.salivarius assays)
• Metabolic Dynamics of In Vitro CD8+ T Cell Activation.
• Multi-Omics Analysis Reveals Disturbance of Nanosecond Pulsed Electric Field in the Serum Metabolic Spectrum and Gut Microbiota
• Mechanical force promotes dimethylarginine dimethylaminohydrolase 1-mediated hydrolysis of the metabolite asymmetric dimethylarginine to enhance bone formation
• Intergenerational Association of Gut Microbiota and Metabolism between Perinatal Folic Acid Metabolism and Neural Tube Defects (Feces metabolomics)
• Mechanism of interventional effect and targets of Zhuyu Pill in regulating and suppressing colitis and cholestasis

Observed in differential profiles

• G4_Eubacterium_rectale_DMSO_30_vs_G3_Eubacterium_rectale_Duloxetine_47
• G3_Experimental_Sample_0h_vs_G11_Experimental_Sample_96h
• Control_vs_nsPEF_7_day
• Control_vs_Exercise
• Normal_vs_Neural_Tube_Defect
• Control_vs_ZYP_High_Dose